{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:46:07Z","timestamp":1778280367864,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40264-021-01121-8","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T14:03:55Z","timestamp":1635170635000},"page":"1375-1390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety Profile of GSK\u2019s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019\/2020 Influenza Season"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-9913","authenticated-orcid":false,"given":"Ignacio","family":"Salamanca de la Cueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9174-6438","authenticated-orcid":false,"given":"Elisa","family":"Cinconze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Eckermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-703X","authenticated-orcid":false,"given":"Ugo","family":"Nwoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4764-8835","authenticated-orcid":false,"given":"Lode","family":"Godderis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4583-9734","authenticated-orcid":false,"given":"Xavier","family":"Mart\u00ednez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7204-6583","authenticated-orcid":false,"given":"Huajun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9026-0735","authenticated-orcid":false,"given":"Emad","family":"Yanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"1121_CR1","unstructured":"European Centre for Disease Prevention and Control. Factsheet about seasonal influenza. ECDC: Stockholm. https:\/\/www.ecdc.europa.eu\/en\/seasonal-influenza\/facts\/factsheet. Accessed 30 Apr 2021."},{"key":"1121_CR2","unstructured":"European Centre for Disease Prevention and Control. Seasonal influenza vaccination and antiviral use in EU\/EEA Member States\u2014Overview of vaccine recommendations for 2017\u20132018 and vaccination coverage rates for 2015\u20132016 and 2016\u20132017 influenza seasons. ECDC: Stockholm; 2018. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/seasonal-influenza-antiviral-use-2018.pdf. Accessed 2 Mar 2021."},{"key":"1121_CR3","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.16.17-00454","author":"A Cassini","year":"2018","unstructured":"Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.16.17-00454.","journal-title":"Euro Surveill"},{"issue":"1","key":"1121_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12889-017-4177-z","volume":"17","author":"G Matias","year":"2017","unstructured":"Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of hospitalization attributable to influenza and RSV in the US during 1997\u20132009, by age and risk status. BMC Public Health. 2017;17(1):271. https:\/\/doi.org\/10.1186\/s12889-017-4177-z.","journal-title":"BMC Public Health"},{"key":"1121_CR5","unstructured":"European Centre for Disease Prevention and Control. Seasonal influenza 2019-2020. Annual Epidemiological Report. ECDC: Stockholm; 2020. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2019_influenza-seasonal.pdf. Accessed 25 Feb 2021."},{"key":"1121_CR6","unstructured":"European Centre for Disease Prevention and Control. Influenza virus characterization, Summary Europe, September 2020. ECDC: Stockholm; 2020. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/influenza-characterisation-report-september-2020.pdf. Accessed 10 Mar 2021."},{"key":"1121_CR7","unstructured":"World Health Organization (WHO). Recommendations on influenza vaccination during the 2019\u20132020 winter season. WHO: Copenhagen; 2019. https:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0017\/413270\/Influenza-vaccine-recommendations-2019-2020_en.pdf. Accessed 6 Jul 2020."},{"key":"1121_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/1471-2458-14-813","volume":"14","author":"E Preaud","year":"2014","unstructured":"Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14:813. https:\/\/doi.org\/10.1186\/1471-2458-14-813.","journal-title":"BMC Public Health"},{"key":"1121_CR9","unstructured":"World Health Organization (WHO). Fact sheets. Influenza (seasonal). 2018. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/influenza-(seasonal). Accessed 9 Jul 2020."},{"key":"1121_CR10","unstructured":"World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. WHO: Geneva; 2020. https:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/en\/. Accessed 9 Jul 2020"},{"key":"1121_CR11","unstructured":"Pharmacovigilance Risk Assessment Committee (PRAC). Guideline on influenza vaccines. Non-clinical and clinical module. EMA\/CHMP\/VWP\/457259\/2014 European Medicines Agency (EMA). London; 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/influenza-vaccines-non-clinical-clinical-module_en.pdf. Accessed 19 Jul 2020."},{"issue":"4","key":"1121_CR12","doi-asserted-by":"publisher","first-page":"e12016","DOI":"10.2196\/12016","volume":"5","author":"S de Lusignan","year":"2019","unstructured":"de Lusignan S, Correa A, Dos Santos G, Meyer N, Haguinet F, Webb R, et al. Enhanced safety surveillance of influenza vaccines in general practice, winter 2015\u201316: feasibility study. JMIR Public Health Surveill. 2019;5(4):e12016. https:\/\/doi.org\/10.2196\/12016.","journal-title":"JMIR Public Health Surveill"},{"issue":"5","key":"1121_CR13","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/21645515.2019.1565258","volume":"15","author":"S de Lusignan","year":"2019","unstructured":"de Lusignan S, Ferreira F, Damaso S, Byford R, Pathirannehelage S, Yeakey A, et al. Enhanced passive surveillance of influenza vaccination in England, 2016\u20132017- an observational study using an adverse events reporting card. Hum Vaccin Immunother. 2019;15(5):1048\u201359. https:\/\/doi.org\/10.1080\/21645515.2019.1565258.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"1121_CR14","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1080\/21645515.2019.1705112","volume":"16","author":"S de Lusignan","year":"2020","unstructured":"de Lusignan S, Damaso S, Ferreira F, Byford R, McGee C, Pathirannehelage S, et al. Brand-specific enhanced safety surveillance of GSK\u2019s Fluarix Tetra seasonal influenza vaccine in England: 2017\/2018 season. Hum Vaccin Immunother. 2020;16(8):1762\u201371. https:\/\/doi.org\/10.1080\/21645515.2019.1705112.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"1121_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40264-019-00893-4","volume":"43","author":"G Dos Santos","year":"2020","unstructured":"Dos Santos G, Nguyen BY, Damaso S, Godderis L, Martinez-Gomez X, Eckermann T, et al. Brand-specific Enhanced Safety Surveillance of GSK\u2019s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain for the 2018\/2019 Season. Drug Saf. 2020;43(3):265\u201379. https:\/\/doi.org\/10.1007\/s40264-019-00893-4.","journal-title":"Drug Saf"},{"key":"1121_CR16","unstructured":"World Health Organization. Seasonal influenza. 2021. https:\/\/www.who.int\/ith\/vaccines\/seasonal_influenza\/en\/. Accessed 10 Mar 2021."},{"key":"1121_CR17","unstructured":"GSK. GSK Study Register. 2019. https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=207749. Accessed 8 Jul 2020."},{"key":"1121_CR18","unstructured":"MedDRA. Medical dictionary for regulatory activities. 2019. https:\/\/www.meddra.org\/basics. Accessed 1 Apr 2019"},{"key":"1121_CR19","unstructured":"GlaxoSmithKline UK. Fluarix Tetra suspension for injection in pre-filled syringe. 2020. https:\/\/www.medicines.org.uk\/emc\/product\/3021\/smpc. Accessed 8 Jul 2020."},{"key":"1121_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/1471-2334-13-343","volume":"13","author":"D Kieninger","year":"2013","unstructured":"Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged \u2265 18 years. BMC Infect Dis. 2013;13:343. https:\/\/doi.org\/10.1186\/1471-2334-13-343.","journal-title":"BMC Infect Dis"},{"issue":"26","key":"1121_CR21","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1215817","volume":"369","author":"VK Jain","year":"2013","unstructured":"Jain VK, Rivera L, Zaman K, Espos RA Jr, Sirivichayakul C, Quiambao BP, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med. 2013;369(26):2481\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1215817.","journal-title":"N Engl J Med"},{"issue":"5","key":"1121_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S2352-4642(18)30062-2","volume":"2","author":"C Claeys","year":"2018","unstructured":"Claeys C, Zaman K, Dbaibo G, Li P, Izu A, Kosalaraksa P, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6\u201335 months: a multinational randomised trial across five influenza seasons. Lancet Child Adolesc Health. 2018;2(5):338\u201349. https:\/\/doi.org\/10.1016\/S2352-4642(18)30062-2.","journal-title":"Lancet Child Adolesc Health."},{"issue":"1","key":"1121_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12879-018-3079-8","volume":"18","author":"C Claeys","year":"2018","unstructured":"Claeys C, Drame M, Garcia-Sicilia J, Zaman K, Carmona A, Tran PM, et al. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults. BMC Infect Dis. 2018;18(1):186. https:\/\/doi.org\/10.1186\/s12879-018-3079-8.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1121_CR24","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1186\/s12889-018-6260-5","volume":"18","author":"S Spila Alegiani","year":"2018","unstructured":"Spila Alegiani S, Alfonsi V, Appelgren EC, Ferrara L, Gallo T, Alicino C, et al. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015\/2016 season. BMC Public Health. 2018;18(1):1401. https:\/\/doi.org\/10.1186\/s12889-018-6260-5.","journal-title":"BMC Public Health"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01121-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T17:06:37Z","timestamp":1637946397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01121-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01121-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"assertion":[{"value":"12 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: 207749) and was involved in all stages of the study, including analysis of the data. GlaxoSmithKline Biologicals SA also took charge of all costs associated with the development and publication of this present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Elisa Cinconze, Ugo Nwoji, Emily Lu, Huajun Wang, and Emad Yanni are employees of the GSK group of companies. Ugo Nwoji, Emily Lu, Huajun Wang, and Emad Yanni hold shares in the GSK group of companies. Xavier Mart\u00ednez G\u00f3mez declares he has received financial support from Pax-Vax for participation on advisory boards for vaccines, from Pfizer for participation at conferences, and from the GSK group of companies for practical courses. Ignacio Salamanca de la Cueva declares he has received grants and\/or honoraria as a consultant\/advisor for attending conferences and practical courses from the GSK group of companies, Sanofi Pasteur, MSD, and Pfizer. Elisa Cinconze, Ugo Nwoji, Emily Lu, Huajun Wang, Emad Yanni, Xavier Mart\u00ednez-G\u00f3mez, and Ignacio Salamanca de la Cueva declare no other financial or non-financial relationships and activities. Tamara Eckermann and Lode Godderis declare no financial and non-financial relationships and activities and no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Anonymised individual participant data and study documents can be requested for further research from .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The following ethics committees (ECs), institutional review boards, and regulatory authorities were consulted in line with country requirements, namely Commissie Medische Ethiek UZ\/KU Leuven (EC) in Belgium (approval received 13 September 2019), Ethik-Kommission der Bayerischen Landes\u00e4rztekammer (EC) in Germany (approval received 13 September 2019), and, in Spain, CCEIBA and CCAA for Andalusia (approval received 25 July 2019) and Vall d\u00b4Hebron, Medicinal Product Research Ethics Committee of Hospital Universitari Vall d\u00b4Hebron (approval received 17 July 2019) and Generalitat de Catalunya, Directorate General of Management and Health Regulation (CCAA) (approval received 25 September 2019) for Catalonia.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent or assent was obtained from all individual participants included in this study or their parent(s), guardian(s), or legally acceptable representative(s) prior to participation in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"All authors participated in the design, implementation, analysis, and interpretation of the study and the development of this manuscript. All authors had full access to the data and gave final approval prior to submission.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"<i>AlphaRix Tetra<\/i>, <i>Influsplit Tetra,<\/i> and <i>Fluarix Tetra<\/i> are trademarks owned by or licensed to the GSK group of companies.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademarks"}}]}}